

AMC Independent Assessment Committee (IAC) Meeting

Summary of Meeting

11 December 2008

Teleconference

IAC Members Participants

- **Claire Broome**, Adjunct Professor Division of Global Health Rollins, School of Public Health Emory University Atlanta, Georgia, USA
- **Ingrid Callies**, Adviser to the Vice-President for Medical Affairs, Institut Pasteur, France
- **Arthur Elliot**, Senior Program Manager, Vaccines and Anti Viral Agents, US Department of Health and Human Services, USA
- **Mary Kitambi**, Program Manager for Expanded Programme on Immunization, Tanzania
- **Tracy Lieu**, Director, Centre for Child Health Care Studies, Harvard Medical School, USA
- **Halvor Sommerfelt**, Professor of Epidemiology, Center for International Health, University of Bergen, Norway
-

GAVI

- **Tania Cernuschi**, AMC Manager

Guests

- **Professor David Goldblatt**, Chair TPP, Professor of Vaccinology and Immunology, Institute of Child Health, University College London and Great Ormond Street Hospital for Children NHS Trust.
- **Joachim Hombach**, Coordinator Implementation Research, Initiative for Vaccine Research (IVR), WHO
- **Orin Levine**, Director PneumoADIP

Purpose of Meeting

The purpose of the meeting was the endorsement of the Technical Product Profile (TPP).

Commencement

The Independent Assessment Committee (IAC) met by a conference call on 11 December 2008. Six of 8 members of the IAC attended the call and a minimum quorum was present as required in the IAC provisional Charter and Bylaw was thus

obtained. The meeting was chaired by Dr. Claire Broome - appointed interim IAC Chair.

Discussion on the TPP

- The discussion focused on the TPP requirement relating to the serotype formulations for pneumococcal conjugate vaccines.
- Differences between version 1 and 2 of the Pneumococcal Global Serotype Project (GSP) the 2 versions were briefly discussed, now that IAC members had been briefed by PneumoADIP on GSP version 2 which provides the definitive metrics to assess whether a pneumococcal vaccine meets the pneumococcal AMC TPP for regional vaccine serotype coverage.
- It was pointed out that properly undertaken impact evaluations of pneumococcal conjugate vaccination, should have a high priority.

DECISIONS

Approved: the endorsement of the TPP with a reference to the global GSP version 2 as the metrics to assess whether a pneumococcal vaccine meets the pneumococcal AMC TPP for regional vaccine serotype coverage.

Agreed WHO, PneumoADIP and GAVI will work together to conduct agreed minor editorial changes to the document and publish it on the AMC website.